Indiana University Comprehensive Training in Clinical Pharmacology

迫切需要训练有素的临床科学家，以加强新疗法的转化为 临床实践，并确保安全有效的用药。印第安纳大学 临床药理学综合培训计划(T32GM008425)，目前在第29年和 培训了50多名临床药理学科学家，寻求继续培养研究员(医学博士、药学博士、 药学博士/博士、DNP、医学博士/博士、博士或同等学历)从事翻译和临床治疗工作。 研究员可以接触到40名尽职尽责、充满活力和多学科参与的教职员工，他们来自广泛的 基础和临床治疗学研究计划的范围(根据研究质量选择25名导师， 同行评审的资金、协作关系和指导承诺，以及15个参与其他 角色)。受训人员在以下其中一人的指导下进行研究(实验室、临床和/或硅学) 训诫。专家之间的合作包括药物基因组学、药物不良反应、药物- 药物相互作用，药物处置，药物发现和开发，定量药理学，儿科 药理学、精确医学、药物反应和治疗结果的生物标志物。受训人员还将 接受广泛的临床药理学问题和技能以及研究道德和责任感方面的正式培训 进行研究，使受训人员为参与研究和实践的复杂性做好准备 转化治疗学。研究员参加专门组织的团队日志俱乐部，以两次打破竖井 每月，每周临床药理学和个体化医学研讨会，以及有组织的教学 每周一次的节目。指导培训集中在PK/PD，药物和代谢物分析， 药物基因组学、定量药理学、生物统计学、临床试验设计、药物发现和 发展、研究道德和负责任的研究行为。培训发生在一次异常的 丰富、协同、互补的培训环境。加强该司的体制支持 它的培训计划也很出色。培训计划继续产生多样化的临床 药理学家，包括妇女和代表不足的少数族裔，他们在 学术界、制药业和监管机构。合资格的申请者总是填写 培训补助金名额。事实上，我们收到的合格申请者比现有职位多得多。我们的 该计划得到了美国临床药理学委员会的认可。因为临床科 印第安纳大学的药理学在培训领导者方面有着悠久而杰出的记录 临床药理学和翻译治疗学，我们的培训计划目前代表着 最强大、最全面和最前沿的培训，我们处于独特的地位，可以成功地继续 培养学科未来的优秀带头人。

There is a critical need of well-trained clinical scientist that can augment the translation of new therapies into clinical practice and to ensure the safe and effective use of medications. The Indiana University Comprehensive Training Program in Clinical Pharmacology (T32GM008425), currently in the 29th year and trained over 50 scientists in clinical pharmacology, seeks to continue preparing fellows (MDs, PharmDs, PharmD/PhDs, DNPs, MD/PhDs, PhDs or equivalent) for careers in translational and clinical therapeutics. Fellows have access to 40 committed, vibrant, and multidisciplinary participating faculty drawn from a broad range of basic and clinical therapeutics research programs (25 preceptors selected based on research quality, peer-reviewed funding, collaborative relationships, and mentoring commitment, and 15 participating in other roles). Trainees conduct research (laboratory, clinical and/or in silico) under the mentorship of one of the preceptors. Collaborations among the preceptors include pharmacogenomics, adverse drug reactions, drug- drug interactions, drug disposition, drug discovery and development, quantitative pharmacology, pediatric pharmacology, precision medicine, biomarker of drug response and therapeutic outcomes. Trainees will also receive formal training in broad clinical pharmacology issues and skills and in research ethics and responsible conduct of research to prepare trainees for the complexities involved in the research and practice of translational therapeutics. Fellows attend team journal clubs specifically organized to break down silos twice monthly, seminars in clinical pharmacology and personalized medicine every week, and an organized didactic program every week. The didactic training concentrates on PK/PD, drug and metabolite analysis, pharmacogenomics, quantitative pharmacology, biostatistics, clinical trial design, drug discovery and development, research ethics and the responsible conduct of research. The training occurs in an exceptionally rich, synergetic, and complementary training environment. The institutional support to strengthen the Division and its training program is outstanding. The training program continues to generate diverse clinical pharmacologists, including women and underrepresented minorities, who have assumed prominent roles in academia, the pharmaceutical industry, and regulatory agencies. Qualified applicants have always filled the training grant slots. In fact, we receive substantially more qualified applicants than available positions. Our program is accredited by the American Board of Clinical Pharmacology. Because the Division of Clinical Pharmacology at Indiana University has a long and distinguished record of excellence in training leaders in clinical pharmacology and translational therapeutics and our training program currently represents one of the strongest, most comprehensive, and cutting-edge training, we are in a unique position to successfully continue training outstanding future leaders in the discipline.